WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year

Rhea-AI Summary

WuXi Biologics (2269.HK) has received a Platinum Award from The Asset ESG Corporate Awards for the fourth consecutive year. This prestigious honor recognizes the company's commitment to sustainable practices and its effective approach to driving innovation and efficiency through green technology.

The Asset evaluates companies on various ESG metrics, including corporate governance, sustainability financing, supplier codes of conduct, energy consumption, GHG emissions, and waste and water management. WuXi Biologics is the only healthcare industry company among this year's winners.

The company has made significant progress in pursuing sustainable development and socially responsible policies, aligning with the United Nations Sustainable Development Goals. WuXi Biologics is a signatory to the UN Global Compact and the Science Based Targets initiative (SBTi) commitment letter.

WuXi Biologics' ESG efforts have been recognized by major rating agencies, receiving accolades such as an 'AAA' rating from MSCI ESG Ratings, a Platinum Medal from EcoVadis, and inclusion in various prestigious ESG indexes.

HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards for the fourth year in a row. The prestigious honor recognizes the company's unwavering commitment to sustainable practices as well as its effective approaches to driving innovation and efficiency through green technology.

As a widely recognized business news and research organization, The Asset evaluates companies regarding their ESG responsibilities for its annual ESG Corporate Awards, reviewing a wide range of metrics, including corporate governance, sustainability financing, supplier codes of conduct, energy consumption and GHG emissions, and waste and water management. WuXi Biologics is the only company in the healthcare industry among this year's winners.

Dr. Chris Chen, WuXi Biologics' CEO and Chairman of the ESG Committee, commented, "We are profoundly pleased to win the Platinum Award for the fourth consecutive year. While we view the award as a celebration of WuXi Biologics' sustainability achievements over the past years, we also see it as an impetus for us to persist further in our sustainability efforts, pushing the boundaries and demonstrating our leadership in the biologics CRDMO industry for a greener and healthier future."

In line with the United Nations Sustainable Development Goals, WuXi Biologics has been making significant progress in pursuing sustainable development and socially responsible policy initiatives. Demonstrating its commitment, the company is a signatory to the United Nations Global Compact, as well as the global Science Based Targets initiative (SBTi) commitment letter.

The company's efforts have been recognized by major ESG rating agencies. It was granted an "AAA" rating from MSCI ESG Ratings; awarded the distinguished Platinum Medal by EcoVadis; included in the DJSI World Index and Emerging Markets Index; named to the MSCI ESG Leaders Indexes; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security "A list" and awarded an "A-" CDP Climate Change score; named a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-receives-esg-corporate-platinum-award-from-the-asset-for-fourth-consecutive-year-302277739.html

SOURCE WuXi Biologics

FAQ

What award did WuXi Biologics (WXXWY) receive in 2024?

WuXi Biologics received a Platinum Award from The Asset ESG Corporate Awards in 2024 for the fourth consecutive year.

How many times has WuXi Biologics (WXXWY) won the Platinum Award from The Asset?

WuXi Biologics has won the Platinum Award from The Asset ESG Corporate Awards for four consecutive years.

What global initiatives has WuXi Biologics (WXXWY) signed?

WuXi Biologics has signed the United Nations Global Compact and the global Science Based Targets initiative (SBTi) commitment letter.

What ESG rating did WuXi Biologics (WXXWY) receive from MSCI?

WuXi Biologics received an 'AAA' rating from MSCI ESG Ratings.

Is WuXi Biologics (WXXWY) included in any ESG indexes?

Yes, WuXi Biologics is included in several ESG indexes, such as the DJSI World Index, MSCI ESG Leaders Indexes, FTSE4Good Index Series, and Hang Seng ESG 50 Index.